Morphosys (DE:MOR) has released an update.
MorphoSys AG has become a majority-owned subsidiary of Novartis following a successful voluntary public takeover offer at €68.00 per share, with Novartis BidCo AG acquiring a stake of approximately 91.04%. The company also sold the rights to tafasitamab to Incyte for $25 million and announced significant changes to its management board and financial guidance post-takeover, including the expectation of no product sales revenues for 2024. Furthermore, MorphoSys’s development pipeline includes partnerships with Novartis and Anthos Therapeutics on multiple clinical programs in various disease areas.
For further insights into DE:MOR stock, check out TipRanks’ Stock Analysis page.
